Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.55 |
| ▸ | DHFR | P00374 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8127441 | 0.85 | FGFR1 (0.78) | FGFR1DHFRSRCPDGFRBPDGFRA | |
| SCHEMBL4200127 | 0.83 | FGFR1 (0.71) | FGFR1DHFRSRCPDGFRBPDGFRA | |
| SCHEMBL4357670 | 0.79 | DHFR (0.50) | FGFR1DHFRNOS3NOS1NOS2 | |
| SCHEMBL4188897 | 0.75 | DHFR (0.54) | FGFR1DHFRLCKKDRJAK3 | |
| SCHEMBL15389064 | 0.74 | DHFR (0.56) | FGFR1DHFRLCKKDRJAK3 | |
| SCHEMBL736022 | 0.72 | DHFR (0.58) | FGFR1DHFRSRCPDGFRBPDGFRA | |
| SCHEMBL8131484 | 0.71 | FGFR1 (1.00) | FGFR1DHFRSRCPDGFRBPDGFRA | |
| SCHEMBL8893950 | 0.71 | DHFR (0.43) | FGFR1DHFRSRCADORA1 | |
| SCHEMBL31656490 | 0.71 | — | — | |
| SCHEMBL879562 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| WO-2007075911-A2 | INHIBITION OF GLYCOGEN SYNTHASE KINASE AND METHODS OF TREATING AUTOIMMUNE OR IMMUNE INFLAMMATORY DISEASE | YALE UNIVERSITY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | FGFR1 1959/4885DHFR 2507/4885SRC 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.